Generic Avelox Availability

Avelox is a brand name of moxifloxacin, approved by the FDA in the following formulation(s):

AVELOX (moxifloxacin hydrochloride - tablet; oral)

  • Manufacturer: BAYER HLTHCARE
    Approval date: December 10, 1999
    Strength(s): EQ 400MG BASE [RLD]

Has a generic version of Avelox been approved?

No. There is currently no therapeutically equivalent version of Avelox available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avelox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
    Patent 5,607,942
    Issued: March 4, 1997
    Inventor(s): Petersen; Uwe & Schenke; Thomas & Krebs; Andreas & Grohe; Klaus & Schriewer; Michael & Haller; Ingo & Metzger; Karl G. & Endermann; Rainer & Zeiler; Hans-Joachim
    Assignee(s): Bayer Aktiengesellschaft
    7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives, of the formula ##STR1## in which X.sup.1 is halogen, X.sup.2 is hydrogen, halogen, amino or other radical, R.sup.1 is alkyl, cycloalkyl, optionally substituted phenyl or other radical, R.sup.2 is hydrogen, alkyl or a dioxolylmethyl radical, R.sup.3 is ##STR2## and A is N, CH, C-halogen, or the like, or forms a bridge with R.sup.1, and addition products thereof.
    Patent expiration dates:
    • March 4, 2014
      ✓ 
      Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
  • Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification
    Patent 5,849,752
    Issued: December 15, 1998
    Inventor(s): Grunenberg; Alfons & Bosche; Patrick
    Assignee(s): Bayer Aktiengesellschaft
    The invention relates to the new monohydrate of 1-cyclopropyl-7-(›S,S!-2,8-diazabicyclo-›4.3.0!non-8-yl)6-fluoro-1,4-dihyd ro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride (CDCH), a process for its preparation and pharmaceutical formulations which comprise this monohydrate as the active compound.
    Patent expiration dates:
    • December 5, 2016
      ✓ 
      Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
  • Pharmaceutical moxifloxacin preparation
    Patent 6,610,327
    Issued: August 26, 2003
    Inventor(s): Patrick; Bosché & Hans Friedrich; Mahler & Claus; Weisemann
    Assignee(s): Bayer Aktiengesellschaft
    The present invention relates to a pharmaceutical preparation for oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.
    Patent expiration dates:
    • October 29, 2019
      ✓ 
      Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web4)